Vol. 3 No. 1 (2026): January - March
75-91
2026-03-30
Open Access

Lipid metabolism and modern approaches to lipid-lowering therapy

Malika U.Yakhyoeva
Rano B.Alieva
Aleksandr B.Shek
DOI: https://doi.org/10.70626/cardiouz-2026-3-00080

Received: 2026-06-17 08:40:21

Published: 2026-03-30

PDF (Russian)
Crossmark Crossmark

Abstract

Lipid metabolism disorders are one of the leading risk factors for the development of atherosclerotic cardiovascular diseases and remain of high importance worldwide. Despite substantial advances in reducing low-density lipoprotein (LDL) cholesterol, many patients still have a residual cardiovascular risk associated with triglyceride-rich lipoproteins, remnant cholesterol, and Lp (a). This review summarizes current information on lipid metabolism, including exogenous and endogenous lipoprotein transport pathways, as well as modern strategies for lipid-lowering therapy, in particular drugs agents targeting PCSK9, ANGPTL3, ApoC III and LP(a). Special attention is paid to promising technologies based on small interfering RNAs, antisense oligonucleotides, and CRISP/Cas9 genomic editing. The collected data indicate that an deeper understanding of the mechanisms of lipid metabolism contributes to the development of innovative treatment methods that can more effectively control dyslipidemia and reduce the risk of cardiovascular complications.

Keywords

List of references

  1. Clinical Protocols, Guidelines, and Recommendations of the Ministry of Health of the Republic of Uzbekistan, 2024. In Russian: Клинические протоколы, руководства, рекомендации Министерства здравоохранения Республики Узбекистан 2024. https://diseases.medelement.com/disease/BD-2024/18879.

  2. Cardiovascular Disease Incidence Rates by Country in 2026. (May 7, 2026). World Population Review. In Russian: Показатели заболеваемости сердечно-сосудистыми заболеваниями в странах в 2026 году. (07.05.2026). Обзор мирового населения. https://worldpopulationreview.com/country-rankings/heart-disease-rates-by-country.

  3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), https://doi.org/10.1093/eurheartj/ehz455.

  4. Anne-Marie K Jepsen, Anne Langsted, Anette Varbo, Lia E Bang, Pia R Kamstrup, Børge G Nordestgaard, Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease, Clinical Chemistry, Volume 62, Issue 4, 1 April 2016, Pages 593–604, https://doi.org/10.1373/clinchem.2015.253757.

  5. Barbieri, L., Tumminello, G., Fichtner, I. et al. PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?. Curr Atheroscler Rep 26, 589–602 (2024). https://doi.org/10.1007/s11883-024-01230-6.

  6. Blom, D. J., Marais, A. D., Raal, F. J. (2025). Homozygous Familial Hypercholesterolemia Treatment: New Developments. Current atherosclerosis reports, 27(1), 22. https://doi.org/10.1007/s11883-024-01269-5.

  7. Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., Mora, S., . . . Wilkins, J. T. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 87(19), 2624–2757. https://doi.org/10.1016/j.jacc.2025.11.016.

  8. Casula, M., Colpani, O., Xie, S., Catapano, A. L., Baragetti, A. (2021). HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. Cells, 10(8), 1869. https://doi.org/10.3390/cells10081869.

  9. Chen, J., Fang, Z., Luo, Q. et al. Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. Lipids Health Dis 23, 14 (2024). https://doi.org/10.118 6/s12944-023-01993-y.

  10. Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., Kozlovski, P., Cao, H., Wang, J., Nissen, S. E. (2025). Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). American heart journal, 287, 1–9. https://doi.org/10.1016/j.ahj.2025.03.019.

  11. Chubykina U.V., Tyurina A.V., Ezhov M.V. The era of targeted therapy for hyperlipidemia. Russian Journal of Cardiology. 2024;29(8):6038. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6038.EDN: YYMUYK.

  12. Duan, Y., Gong, K., Xu, S. et al. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Sig Transduct Target Ther 7, 265 (2022). https://doi.org/10.1038/s4 1392-022-01125-5.

  13. Feingold, K. R. (2024). Introduction to Lipids and Lipoproteins. In K. R. Feingold (Eds.) et. al., Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/.

  14. Ginsberg, H. N., Packard, C. J., Chapman, M. J., Bore´n, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard,

  15. B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M. R., Tokgo¨ zog˘ lu, L. S., Tybjaerg-Hansen, A., . . . Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. European heart journal, 42(47), 4791–4806. https://doi.org/10.1093/eurheartj/ehab551.

  16. Gouni-Berthold, I., Schwarz, J., Berthold, H. K. (2023). Updates in Drug Treatment of Severe Hypertriglyceridemia. Current atherosclerosis reports, 25(10), 701–709. https://doi.org/10.1007/s1 1883-023-01140-z.

  17. Griffiths, W. J., Wang, Y. (2021). Sterols, Oxysterols, and Accessible Cholesterol: Signalling for Homeostasis, in Immunity and During Development. Frontiers in physiology, 12, 723224. https://doi.org/ 10.3389/fphys.2021.723224.

  18. Gugliucci A. (2023). Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux. Journal of clinical medicine, 12(13), 4399. https://doi.org/10.3390/jcm12134399.

  19. Izar, M. C., Fonseca, F. A. H. (2025). Novel Therapeutics for Familial Chylomicronemia Syndrome. Current atherosclerosis reports, 27(1), 51. https://doi.org/10.1007/s11883-025-01295-x.

  20. Katsiki, N., Vrablik, M., Banach, M., Gouni-Berthold, I. (2025). Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?. Pharmaceuticals (Basel, Switzerland), 18(5), 753. https://doi.org/10.3390/ph18050753.

  21. Kindel, T., Lee, D. M., Tso, P. (2010). The mechanism of the formation and secretion of chylomicrons. Atherosclerosis. Supplements, 11(1), 11–16. https://doi.org/10.1016/j.atherosclerosissup.2010.03.003.

  22. Kosmas, C. E., Bousvarou, M. D., Papakonstantinou, E. J., Tsamoulis, D., Koulopoulos, A., Echavarria Uceta, R., Guzman, E., Rallidis, L. S. (2023). Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a). International journal of molecular sciences, 24(17), 13622. https://doi.org/10.3 390/ijms241713622.

  23. Kosmas, C. E., Bousvarou, M. D., Tsamoulis, D., Gianniou, M., Papakonstantinou, E. J., Rallidis, L. S. (2025). Novel RNA-Based Therapies in the Management of Dyslipidemias. International journal of molecular sciences, 26(3), 1026. https://doi.org/10.3390/ijms26031026.

  24. Kosmas, C. E., Rallidis, L. S., Hoursalas, I., Papakonstantinou, E. J., Kostara, C. E. (2026). Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias. International journal of molecular sciences, 27(2), 921. https://doi.org/10.3390/ijms27020921.

  25. Kounatidis D, Vallianou NG, Poulaki A, Evangelopoulos A, Panagopoulos F, Stratigou T, Geladari E, Karampela I, Dalamaga M. ApoB100 and Atherosclerosis: What’s New in the 21st Century? Metabolites. 2024; 14(2):123. https://doi.org/10.3390/metabo14020123.

  26. Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Baker, J., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., Nissen, S. E. (2025). Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. The New England journal of medicine, 393(21), 2119–2130. https://doi.org/10.1056/NEJMoa2511778.

  27. Laguna-Maldonado, K. D., Uribe-Ram´ırez, D., Va´zquez-Carrada, M., Matuz-Mares, D., Vilchis-Landeros, M. M. (2025). Dysfunction of the ABCA1 and ABCG1 Transporters and Their Impact on HDL Metabolism. Antioxidants (Basel, Switzerland), 14(11), 1362. https://doi.org/10.3390/antiox14111362.

  28. Lawler, P. R., Akinkuolie, A. O., Chu, A. Y., Shah, S. H., Kraus, W. E., Craig, D., Padmanabhan, L., Glynn, R. J., Ridker, P. M., Chasman, D. I., Mora, S. (2017). Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. Journal of the American Heart Association, 6(7), e005549. https://doi.org/10.1161/JAHA.117.005549.

  29. Li, T., Yang, Y., Qi, H. et al. CRISPR/Cas9 therapeutics: progress and prospects. Sig Transduct Target Ther 8, 36 (2023). https://doi.org/10.1038/s41392-023-01309-7.

  30. Llop, D., Ray, K. K. (2026). Solbinsiran, a durable GalNAc-conjugated siRNA targeting ANGPTL3 in adults with mixed dyslipidaemia (PROLONG-ANG3):lessons from a randomized, placebo-controlled, phase 2 trial. Cardiovascular research, 122(7), 797–800. https://doi.org/10.1093/cvr/cvag045.

  31. Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., Tokgozoglu, L., . . . ESC Scientific Document Group (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455.

  32. Nicholls S. J. (2023). PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives. Kardiologia polska, 81(2), 115–122. https://doi.org/10.33963/KP.a2023.0030.

  33. Nicholls S. J. (2024). Therapeutic Potential of Lipoprotein(a) Inhibitors. Drugs, 84(6), 637–643. https://doi.org/10.1007/s40265-024-02046-z.

  34. Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., Son, V., Gaudet, D. (2020). Evinacumab in Patients with Refractory Hypercholesterolemia. The New England journal of medicine, 383(24), 2307–2319. https://doi.org/10.1056/NEJMoa2031049.

  35. Shi, Q., Chen, J., Zou, X., Tang, X. (2022). Intracellular Cholesterol Synthesis and Transport. Frontiers in cell and developmental biology, 10, 819281. https://doi.org/10.3389/fcell.2022.819281.

  36. Vanuzzo, D. The epidemiological concept of residual risk. Intern Emerg Med 6 (Suppl 1), 45 (2011). https://doi.org/10.1007/s11739-011-0669-5.

  37. Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, Yogeyaa S. Chibber, Hussein ElBadawi, Marat Ezhov, Michel P. Hermans, Ramesh Chandra Pandey, Kausik K. Ray, Lale Tokgo¨ zoglu, Alberto Zambon, Jean-Pascal Berrou, Michel Farnier, Non HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook, Atherosclerosis, Volume 383, 2023, 117312, ISSN 0021-9150, https://doi.org/10.1016/j.atherosclerosis.2023.117312.

  38. Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., Crooke, S. T., Witztum, J. L., Stroes, E. S., Tsimikas, S. (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet (London, England), 388(10057), 2239–2253. https://doi.org/10.1016/S0140-6736(16)31009-1.

  39. Sylv ers-Davie, K. L., Davies, B. S. J. (2021). Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. American journal of physiology. Endocrinology and metabolism, 321(4), E493–E508. https://doi.org/10.1152/ajpendo.00195.2021.

About the Authors

Malika U.Yakhyoeva
myakh39@outlook.com
Republican Specialized Scientific and Practical Medical Center of Cardiology
Rano B.Alieva
ranoalieva@mail.ru
Republican Specialized Scientific and Practical Medical Center of Cardiology
Aleksandr B.Shek
shek-999@mail.ru
Republican Specialized Scientific and Practical Medical Center of Cardiology

License

Copyright (c) 2026 М.У. Яхъёева, Р.Б. Алиева, А.Б. Шек (Автор)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Lipid metabolism and modern approaches to lipid-lowering therapy (M. Yakhyoeva, R. Alieva, & A. Shek, Trans.). (2026). CARDIOLOGY OF UZBEKISTAN, 3(1), 75-91. https://doi.org/10.70626/cardiouz-2026-3-00080
Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.

ISSN 3060-4850 (Print)